Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.11T
Market cap1.11T
Price-Earnings ratio
40.07
Price-Earnings ratio40.07
Dividend yield
0.57%
Dividend yield0.57%
Average volume
2.22M
Average volume2.22M
High today
$1,179.82
High today$1,179.82
Low today
$1,152.00
Low today$1,152.00
Open price
$1,156.36
Open price$1,156.36
Volume
1.39M
Volume1.39M
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$783.85
52 Week low$783.85

Stock Snapshot

With a market cap of 1.11T, Eli Lilly(LLY) trades at $1,177.05. The stock has a price-to-earnings ratio of 40.07 and currently yields dividends of 0.57%.

During the trading session on 2026-10-11, Eli Lilly(LLY) shares reached a daily high of $1,179.82 and a low of $1,152.00. At a current price of $1,177.05, the stock is +2.2% higher than the low and still -0.2% under the high.

Trading activity shows a volume of 1.39M, compared to an average daily volume of 2.22M.

The stock's 52-week range extends from a low of $783.85 to a high of $1,292.65.

The stock's 52-week range extends from a low of $783.85 to a high of $1,292.65.

LLY News

TipRanks 5h
Eli Lilly Stock: Why Taking Profits Could Make Sense Ahead of 2027

Shares of drug maker Eli Lilly (LLY) have modestly underperformed the S&P 500 (SPY) in 2026, with large-cap U.S. stock returns increasingly driven by AI benefic...

Simply Wall St 11h
Eli Lilly Reported Broader Biomarker Effects In Phase 3b Psoriasis Trial

Eli Lilly (NYSE: LLY) reported new exploratory data from the TOGETHER-PsO Phase 3b trial on combined Taltz and Zepbound use in adults with moderate to severe pl...

Eli Lilly Reported Broader Biomarker Effects In Phase 3b Psoriasis Trial
24/7 Wall St. 2d
Eli Lilly's Biggest Shareholder Just Filed to Sell $347 Million of Stock

Investing Eli Lilly’s Biggest Shareholder Just Filed to Sell $347 Million of Stock Lilly's largest shareholder just filed to unload nearly $350 million in stock...

Eli Lilly's Biggest Shareholder Just Filed to Sell $347 Million of Stock

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

24/7 Wall St. 2d
Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks

Investing Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVi...

Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks
TipRanks 2d
Eli Lilly announces new TOGETHER-PsO trial data

Eli Lilly (LLY) announced new exploratory data from the TOGETHER-PsO Phase 3b clinical trial evaluating the concomitant use of Taltz and Zepbound compared with...

TipRanks 2d
Eli Lilly price target lowered to $1,341 from $1,344 at BofA

BofA analyst Jason Gerberry lowered the firm’s price target on Eli Lilly (LLY) to $1,341 from $1,344 and keeps a Buy rating on the shares as part of the firm’s...

Simply Wall St 2d
Top 3 Biotech Stocks To Watch In October 2026

Bond giant Pimco now sees a real chance of US 10 year Treasury yields hitting 6%, which pulls money toward safer income and makes investors choosier about where...

Top 3 Biotech Stocks To Watch In October 2026
The Motley Fool 3d
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.

UBS analyst Michael Yee clearly preferred Eli Lilly (LLY -1.61%) over Novo Nordisk (NVO -0.21%) in a recent discussion with CNBC. Describing Eli Lilly as a grow...

UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
Zacks 3d
Top Analyst Reports for Eli Lilly, Procter & Gamble & Shell

Thursday, October 8, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research report...

Top Analyst Reports for Eli Lilly, Procter & Gamble & Shell
TipRanks 3d
Lilly’s Oral Orforglipron Trial Targets Early Obesity Risks, Raising the Stakes in Weight-Loss Pharma

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) is running a Phase 3 trial called “A Study of Orfo...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.